僵直性脊椎炎治疗市场，2028-全球产业规模、份额、趋势、机会与预测，2018-2028 依药物、最终用途、地区、竞争细分。

2022 年，全球僵直性脊椎炎治疗市场价值为 46.6 亿美元，预计在预测期内将出现令人印象深刻的增长，到 2028 年CAGR为6.24%。强直性脊椎炎治疗(AS) 是一种慢性发炎性自体免疫疾病，主要影响脊柱，导致疼痛、僵硬和活动能力下降。这种情况是脊椎关节炎疾病的一部分，它也会影响其他关节和器官。近年来，在研究进步、创新疗法和认识不断提高的推动下，全球僵直性脊椎炎治疗市场取得了重大发展。僵直性脊椎炎治疗的特征是连接脊椎底部（骶骨）和骨盆的骶髂关节发炎。随着时间的推移，这种发炎会导致脊椎融合，导致灵活性丧失和姿势改变。这种疾病通常在成年早期开始，出现下背痛和晨僵等症状。早期诊断和有效管理对于改善患者的生活品质至关重要。 AS 是一个全球性问题，影响着全世界数百万人。不同地区的确切盛行率有所不同，某些族群的盛行率较高。虽然 AS 的病因尚不清楚，但遗传因素，尤其是 HLA-B27 基因，在其发生过程中扮演重要角色。

由于多种因素，全球 AS 市场近年来出现了大幅成长。医疗保健专业人员和患者意识的提高导致了早期诊断和治疗，从而促进了整体市场的成长。肿瘤坏死因子 (TNF) 抑制剂等生物药物的出现彻底改变了 AS 治疗。这些药物针对免疫系统的特定组成部分，提供更有效的症状管理。製药公司正在大力投资研发，以确定新的治疗标靶和药物。这导致了一系列处于不同开发阶段的潜在治疗方法。 AS 更常见于年轻人，随着全球人口老化，AS 患者数量预计将增加，从而推动市场扩张。

AS 的治疗主要着重于症状管理、缓解疼痛和减缓疾病进展。非类固醇类抗发炎药 (NSAID) 通常用于缓解疼痛和发炎。此外，物理治疗和运动在维持关节活动度方面发挥着至关重要的作用。生物疗法，例如 TNF 抑制剂（例如阿达木单抗、依那西普），彻底改变了 AS 治疗。这些药物可以有效减轻炎症，并提高患者的生活品质。然而，它们的成本很高，并且存在潜在的副作用，包括增加感染的可能性。

市场概况
预测期	2024-2028
2022 年市场规模	46.6亿美元
2028 年市场规模	66.4亿美元
2023-2028 年CAGR	6.24%
成长最快的细分市场	医院
最大的市场	北美洲

全球 AS 市场可望进一步成长和创新。几个关键趋势和发展正在塑造其未来。正在进行的研究正在发现 TNF 抑制剂以外的新治疗标靶和潜在治疗药物。这包括针对白细胞介素和其他免疫系统成分的药物。遗传学和生物标记研究的进步为个人化治疗方法铺平了道路，确保患者接受适合其特定需求的最有效的治疗。随着一些生物药物的专利到期，生物相似药的引入可能会提高负担能力和获得有效治疗的机会。远距医疗的整合使僵直性脊椎炎患者更容易获得医疗保健，实现远距监控和咨询，特别是对于行动不便的个人而言。

目录

第 1 章：产品概述

• 市场定义
• 市场范围
  • 涵盖的市场
  • 考虑学习的年份
  • 主要市场区隔

第 2 章：研究方法

• 研究目的
• 基线方法
• 主要产业伙伴
• 主要协会和二手资料来源
• 预测方法
• 数据三角测量与验证
• 假设和限制

第 3 章：执行摘要

第 4 章：客户之声

第 5 章：全球僵直性脊椎炎治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依药物分类（Cosentyx、Humira、Simponi、Remicade、Enbrel、Cimzia）
  • 依最终用途（医院、诊所、其他）
  • 按地区
  • 按公司划分 (2022)
• 市场地图

第 6 章：北美僵直性脊椎炎治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按药物分类
  • 按最终用途
  • 按国家/地区
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第 7 章：欧洲僵直性脊椎炎治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按药物分类
  • 按最终用途
• 欧洲：国家分析
  • 德国
  • 英国
  • 义大利
  • 法国
  • 西班牙

第 8 章：亚太地区僵直性脊椎炎治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按药物分类
  • 按最终用途
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第 9 章：南美洲僵直性脊椎炎治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按药物分类
  • 按最终用途
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲僵直性脊椎炎治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按药物分类
  • 按最终用途
• MEA：国家分析
  • 南非僵直性脊椎炎治疗
  • 沙乌地阿拉伯僵直性脊椎炎治疗
  • 阿联酋僵直性脊椎炎治疗

第 11 章：市场动态

• 司机
• 挑战

第 12 章：市场趋势与发展

• 併购
• 药物开发
• 最近的发展

第 13 章：全球僵直性脊椎炎治疗市场：SWOT 分析

第14章：竞争格局

• 商业概览
• 应用程式产品
• 最近的发展
• 主要人员
• SWOT分析
  • AbbVie, Inc.
  • Amgen, Inc.
  • Pfizer, Inc.
  • Novartis AG
  • Eli Lilly and Company
  • UCB, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.

第 15 章：策略建议

关于我们及免责声明

The Global Ankylosing Spondylitis Therapeutics Market has valued at USD 4.66 billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 6.24% through 2028. Ankylosing Spondylitis Therapeutics (AS) is a chronic inflammatory autoimmune disease that primarily affects the spine, leading to pain, stiffness, and decreased mobility. This condition is part of a group of disorders known as spondyloarthritis, which can also affect other joints and organs. The global Ankylosing Spondylitis Therapeutics market has been witnessing significant developments in recent years, driven by advances in research, innovative therapies, and increasing awareness. Ankylosing Spondylitis Therapeutics is characterized by inflammation of the sacroiliac joints, which connect the base of the spine (sacrum) to the pelvis. Over time, this inflammation can lead to the fusion of spinal vertebrae, causing a loss of flexibility and posture changes. The disease typically begins in early adulthood, with symptoms such as lower back pain and morning stiffness. Early diagnosis and effective management are crucial for improving patients' quality of life. AS is a global concern, affecting millions of people worldwide. The exact prevalence varies among different regions, with higher rates in certain populations. While the cause of AS remains unclear, genetic factors, particularly the HLA-B27 gene, play a significant role in its development.

The global AS market has witnessed substantial growth in recent years due to several factors. Improved awareness among healthcare professionals and patients has led to earlier diagnosis and treatment, enhancing the overall market growth. The advent of biologic drugs, such as tumor necrosis factor (TNF) inhibitors, has revolutionized AS treatment. These drugs target specific components of the immune system, providing more effective symptom management. Pharmaceutical companies are investing heavily in research and development to identify novel therapeutic targets and drugs. This has resulted in a pipeline of potential treatments in various stages of development. AS is more commonly diagnosed in younger adults, and as the global population ages, the number of AS patients is expected to rise, driving market expansion.

The treatment of AS primarily focuses on symptom management, pain relief, and slowing down disease progression. Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed to alleviate pain and inflammation. Additionally, physical therapy and exercise play a crucial role in maintaining joint mobility. Biologic therapies, such as TNF inhibitors (e.g., adalimumab, etanercept), have revolutionized AS treatment. These drugs can effectively reduce inflammation and improve patients' quality of life. However, they come with a significant cost and potential side effects, including increased susceptibility to infections.

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 4.66 Billion
Market Size 2028	USD 6.64 Billion
CAGR 2023-2028	6.24%
Fastest Growing Segment	Hospitals
Largest Market	North America

The global AS market is poised for further growth and innovation. Several key trends and developments are shaping its future. Ongoing research is uncovering new treatment targets and potential therapeutic agents beyond TNF inhibitors. This includes drugs targeting interleukins and other immune system components. Advancements in genetics and biomarker research are paving the way for personalized treatment approaches, ensuring that patients receive the most effective therapies tailored to their specific needs. As patents for some biologic drugs expire, the introduction of biosimilars may increase affordability and access to effective treatments. The integration of telemedicine is making healthcare more accessible for AS patients, allowing remote monitoring and consultations, particularly relevant for individuals with limited mobility.

Key Market Drivers

increasing prevalence of Ankylosing Spondylitis Therapeutics is Driving the Global Ankylosing Spondylitis Therapeutics Market

Ankylosing Spondylitis Therapeutics (AS) is a chronic and potentially debilitating inflammatory condition that primarily affects the spine and sacroiliac joints. Over the past few decades, the prevalence of AS has been steadily increasing worldwide, leading to a growing demand for effective treatment options. This rise in AS cases has not only impacted the lives of individuals but has also driven the growth of the global Ankylosing Spondylitis Therapeutics market. Ankylosing Spondylitis Therapeutics is a type of autoimmune disease that primarily affects the axial skeleton, including the spine, pelvis, and hip joints. It is characterized by inflammation, pain, and stiffness, often leading to fusion of the spinal vertebrae and reduced mobility. AS typically strikes individuals in their late teens to early 40s, although it can affect people of all ages. Historically, AS has been considered a rare condition, but recent epidemiological studies have shown a different trend. The exact cause of AS remains unknown, but a combination of genetic and environmental factors is believed to play a significant role in its development. Genetic factors, particularly the presence of the HLA-B27 gene, increase the risk of developing AS. Environmental factors such as smoking and bacterial infections have also been linked to the disease.

One key factor contributing to the increasing prevalence of AS is improved diagnostic techniques. Medical advancements, including the development of more sensitive imaging tools like magnetic resonance imaging (MRI) and better awareness among healthcare professionals, have led to earlier and more accurate diagnoses. Changes in population demographics, including an aging population and shifts in lifestyle and diet, have contributed to the rise in AS cases. As people live longer and engage in different activities, the likelihood of developing AS increases. There is now greater awareness of AS among both patients and healthcare providers. This has led to increased reporting of symptoms and early detection, resulting in more cases being documented in medical records. The genetic component of AS remains a significant factor. Those with a family history of AS or possessing the HLA-B27 gene are at a higher risk, and as genetic factors continue to play a role in our population, more cases are likely to emerge.

The rising prevalence of AS has had a direct impact on the global Ankylosing Spondylitis Therapeutics market. Pharmaceutical companies, healthcare providers, and researchers have recognized the need for more effective treatments and therapies to address the increasing number of AS cases. As a result, the market for AS treatments has experienced significant growth.

Increasing Patient Advocacy and Awareness Fuels Growth in Global Ankylosing Spondylitis Therapeutics Market

Over the past decade, patient advocacy groups and individuals living with AS have played a pivotal role in raising awareness about the condition. These advocates have worked tirelessly to educate the public, healthcare professionals, and policymakers about AS, its symptoms, and the importance of early diagnosis and treatment. They have used various platforms, including social media, support groups, and awareness campaigns, to share their experiences and knowledge. One of the most significant achievements of patient advocacy groups has been the development of educational resources and tools that empower both patients and healthcare providers. These resources help in recognizing the signs and symptoms of AS, promoting early diagnosis, and providing guidance on available treatments and management strategies.

Patient advocacy groups have collaborated with healthcare organizations, pharmaceutical companies, and government agencies to launch awareness campaigns and initiatives aimed at AS. These efforts have contributed to a broader understanding of the disease, resulting in earlier diagnosis and improved patient outcomes.

Patient advocacy groups have established online communities and forums where individuals with AS can connect, share their stories, and seek advice from peers. These communities provide a sense of belonging and enable patients to stay informed about the latest developments in AS research and treatment. Pharmaceutical companies have partnered with patient advocacy groups to launch disease awareness campaigns. These campaigns often feature educational materials, social media outreach, and public events to educate the public about AS.

Greater awareness has led to more individuals seeking medical attention at the onset of AS symptoms. Early diagnosis and intervention are crucial for managing the disease effectively. As a result, the demand for AS medications and therapies has increased. Pharmaceutical companies have been motivated to invest in research and development efforts aimed at discovering more effective treatments for AS. These efforts have resulted in the development of innovative therapies that offer improved outcomes for patients. The growing prevalence of AS diagnoses has expanded the global AS market. It has created opportunities for pharmaceutical companies to introduce new medications and treatments, leading to market growth. The patient advocacy movement has encouraged a patient-centric approach in the healthcare industry. This shift emphasizes the importance of involving patients in decision-making processes, which has led to more tailored treatments and better patient experiences.

Key Market Challenges

Limited Awareness and Early Diagnosis

One of the fundamental challenges in the AS market is the lack of awareness among both healthcare professionals and the general public. AS is often misdiagnosed or diagnosed late, delaying proper treatment and potentially worsening the patient's condition. Raising awareness about the disease, its symptoms, and the importance of early diagnosis is crucial to improving patient outcomes.

Complex Diagnosis and Misdiagnosis

AS diagnosis can be challenging due to its variable symptoms and the need for specialized tests, such as HLA-B27 genetic testing and imaging studies like MRI or X-rays. Misdiagnosis or delayed diagnosis can lead to inadequate treatment and prolonged suffering for patients. Ensuring that healthcare providers have access to the necessary tools and knowledge for accurate diagnosis is essential.

Limited Treatment Options

While there have been significant advancements in AS treatments over the years, there remains a limited number of approved drugs specifically targeting this condition. The market lacks diversity in treatment options, which can result in patients not responding well to available therapies. Expanding the treatment arsenal is essential to meet the unique needs of individual patients.

High Treatment Costs

Biologic medications, which are commonly used in AS treatment, can be prohibitively expensive. High treatment costs create barriers to access for many patients, particularly those without adequate insurance coverage. Reducing the financial burden of AS treatments is necessary to ensure that all patients can receive the care they need.

Side Effects and Safety Concerns

Biologic medications, though effective, may come with a range of side effects and long-term safety concerns. Balancing the benefits of treatment with potential risks can be challenging for both patients and healthcare providers. Continuous research into safer treatment options and better management of side effects is essential.

Variability in Disease Presentation

Ankylosing Spondylitis Therapeutics exhibits considerable variability in disease presentation, making it difficult to develop standardized treatment approaches. Tailoring treatments to individual patients' need and disease severity can be a complex process that requires a deep understanding of the disease.

Limited Research and Development

Compared to other autoimmune diseases, AS has received relatively less attention in terms of research and development. A lack of investment in AS research can slow down the development of new therapies and hinder progress in the market.

Access to Specialized Care

Access to healthcare professionals with expertise in AS management is limited in many regions. Patients often struggle to find rheumatologists and other specialists who are knowledgeable about the disease, resulting in suboptimal care.

Key Market Trends

Technological Advancements

The accurate and early diagnosis of AS is crucial for effective management. Technological advancements have revolutionized the way AS is diagnosed. Magnetic Resonance Imaging (MRI) and computed tomography (CT) scans are now widely used to detect inflammation and structural damage in the spine and sacroiliac joints. These imaging techniques offer high-resolution images, allowing healthcare professionals to identify AS at its early stages when treatment can be most effective. Additionally, the development of AI-driven image analysis tools has improved the speed and accuracy of AS diagnosis. Machine learning algorithms can analyze MRI and CT scans to identify subtle changes that might be missed by human radiologists, ensuring earlier and more accurate diagnoses.

In the past, AS was primarily managed with non-steroidal anti-inflammatory drugs (NSAIDs) and physical therapy. However, technological advancements in the field of biotechnology have given rise to a new class of drugs known as biological therapies. These medications target specific proteins in the immune system that contribute to the inflammation seen in AS. Biological therapies, such as tumor necrosis factor (TNF) inhibitors, have been a game-changer for AS patients. These drugs have shown remarkable efficacy in reducing pain, inflammation, and stiffness associated with the condition. Moreover, the development of biosimilars, which are more affordable versions of biologics, has increased accessibility to these life-changing treatments.

The COVID-19 pandemic accelerated the adoption of telemedicine and remote monitoring technologies across various medical specialties, including rheumatology. For AS patients, this has meant easier access to healthcare professionals and improved disease management. Telemedicine allows individuals with AS to consult with rheumatologists and other specialists from the comfort of their homes, reducing the need for travel and facilitating more frequent check-ups. Patients can discuss their symptoms, medication adjustments, and treatment plans with their healthcare providers through video calls and secure messaging platforms. Furthermore, wearable devices and smartphone apps have enabled remote monitoring of AS symptoms. These technologies can track physical activity, sleep patterns, and pain levels, providing valuable data for both patients and healthcare providers to better understand and manage the disease.

The internet and mobile applications have made it easier for AS patients to access information, educational resources, and support networks. Online platforms and mobile apps provide a wealth of information about AS, including its symptoms, treatment options, and lifestyle recommendations. Patients can also connect with others who share their experiences, providing emotional support and practical advice. Additionally, chatbots and virtual assistants powered by AI have been developed to answer common questions and provide real-time assistance to AS patients. These tools are available 24/7, offering immediate help when needed.

Segmental Insights

Drug Insights

Based on the drug, the humira drug segment emerged as the dominant player in the global market for Ankylosing Spondylitis Therapeutics Market in 2022. Humira has demonstrated efficacy in reducing the symptoms and progression of ankylosing spondylitis in numerous clinical trials. It is known to alleviate pain, stiffness, and inflammation in patients with AS. Its proven track record made it a trusted and go-to option for both patients and healthcare providers. Humira is a biologic drug, specifically a tumor necrosis factor-alpha (TNF-alpha) inhibitor. AS is believed to involve an overproduction of TNF-alpha, which plays a key role in inflammation. By inhibiting TNF-alpha, Humira helps to control the inflammatory response and manage the symptoms of AS. While Humira does come with potential side effects, its safety profile has been well-documented through extensive clinical use. This gave patients and healthcare providers confidence in its use. Humira is administered via subcutaneous injections, which many patients find more convenient than intravenous infusions. Its dosing schedule is typically every two weeks or once a month, depending on the specific condition and the patient's response. This ease of administration improves patient compliance. By the time of my last update, Humira had been on the market for many years and had gained extensive experience and data regarding its use in AS. This long-term presence allowed it to become a trusted and widely prescribed treatment option. The manufacturer, AbbVie, invested heavily in marketing and promotion of Humira, making it a well-recognized brand in the AS treatment space. This branding helped maintain its dominant position in the market. Due to its patent protection and intellectual property rights, Humira had limited competition from biosimilar products until those patents began to expire in certain regions, leading to the eventual introduction of biosimilar versions of adalimumab. Many insurance plans covered Humira, making it more accessible and affordable for patients.

End Use Insights

The hospital segment is projected to experience rapid growth during the forecast period. Hospitals typically have specialized departments or units, such as rheumatology departments, that focus on treating autoimmune diseases like ankylosing spondylitis. Rheumatologists, who are experts in managing AS, are more commonly found in hospital settings. This specialization is crucial for providing the best care and treatment options for AS patients. Hospitals often have access to the latest and most advanced treatments for ankylosing spondylitis. This may include biologic therapies, which have shown efficacy in managing the condition. These therapies are often administered in a hospital setting, requiring close monitoring due to potential side effects. Ankylosing spondylitis can lead to physical limitations, and rehabilitation services such as physical therapy are often an integral part of the treatment plan. Hospitals typically offer comprehensive rehabilitation services, which can be essential for AS patients in improving their mobility and quality of life. The management of AS may require a multidisciplinary approach involving rheumatologists, physical therapists, orthopedic surgeons, and other specialists. Hospitals are well-suited to facilitate collaboration among these healthcare professionals to provide comprehensive care for AS patients. AS patients may experience complications or exacerbations of their condition that require emergency medical attention. Hospitals are equipped to handle such situations, ensuring timely and appropriate care in case of emergencies. Hospitals often engage in research and clinical trials related to ankylosing spondylitis. This research can lead to the development of new treatments and therapies, further solidifying their role in the AS market.

Regional Insights

North America emerged as the dominant player in the global Ankylosing Spondylitis Therapeutics market in 2022, holding the largest market share in terms of value North America, particularly the United States and Canada, boasts advanced healthcare infrastructures with a high concentration of hospitals, clinics, and healthcare professionals. This allows for easier access to diagnosis and treatment of AS, making it a significant player in the global market. North America is home to many pharmaceutical and biotechnology companies with substantial resources dedicated to research and development of AS treatments. These companies often conduct clinical trials and bring innovative therapies to market, contributing to the region's dominance. North America has stringent regulatory agencies like the U.S. Food and Drug Administration (FDA) and Health Canada, which ensure the safety and efficacy of new AS treatments. These agencies often set the standards for the approval of drugs and therapies, attracting investments and fostering innovation.

Key Market Players

AbbVie, Inc.

Amgen, Inc.

Pfizer, Inc.

Novartis AG

Eli Lilly and Company

UCB, Inc.

Johnson & Johnson Services, Inc.

Merck & Co., Inc

Report Scope:

In this report, the Global Ankylosing Spondylitis Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Ankylosing Spondylitis Therapeutics Market, By Drug:

• Cosentyx
• Humira
• Simponi
• Remicade
• Enbrel
• Cimzia

Ankylosing Spondylitis Therapeutics Market, By End Use:

• Hospitals
• Clinics
• Others

Ankylosing Spondylitis Therapeutics Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Ankylosing Spondylitis Therapeutics Market.

Available Customizations:

• Global Ankylosing Spondylitis Therapeutics market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

4. Voice of Customer

5. Global Ankylosing Spondylitis Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug (Cosentyx, Humira, Simponi, Remicade, Enbrel, Cimzia)
  • 5.2.2. By End Use (Hospitals, Clinics, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2022)
• 5.3. Market Map

6. North America Ankylosing Spondylitis Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug
  • 6.2.2. By End Use
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Ankylosing Spondylitis Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug
      • 6.3.1.2.2. By End Use
  • 6.3.2. Canada Ankylosing Spondylitis Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug
      • 6.3.2.2.2. By End Use
  • 6.3.3. Mexico Ankylosing Spondylitis Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug
      • 6.3.3.2.2. By End Use

7. Europe Ankylosing Spondylitis Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug
  • 7.2.2. By End Use
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Ankylosing Spondylitis Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug
      • 7.3.1.2.2. By End Use
  • 7.3.2. United Kingdom Ankylosing Spondylitis Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug
  • 7.3.3. Italy Ankylosing Spondylitis Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Drug
      • 7.3.3.2.2. By End Use
  • 7.3.4. France Ankylosing Spondylitis Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug
      • 7.3.4.2.2. By End Use
  • 7.3.5. Spain Ankylosing Spondylitis Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug
      • 7.3.5.2.2. By End Use

8. Asia-Pacific Ankylosing Spondylitis Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug
  • 8.2.2. By End Use
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Ankylosing Spondylitis Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug
      • 8.3.1.2.2. By End Use
  • 8.3.2. India Ankylosing Spondylitis Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug
      • 8.3.2.2.2. By End Use
  • 8.3.3. Japan Ankylosing Spondylitis Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug
      • 8.3.3.2.2. By End Use
  • 8.3.4. South Korea Ankylosing Spondylitis Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug
      • 8.3.4.2.2. By End Use
  • 8.3.5. Australia Ankylosing Spondylitis Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug
      • 8.3.5.2.2. By End Use

9. South America Ankylosing Spondylitis Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug
  • 9.2.2. By End Use
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Ankylosing Spondylitis Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug
      • 9.3.1.2.2. By End Use
  • 9.3.2. Argentina Ankylosing Spondylitis Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug
      • 9.3.2.2.2. By End Use
  • 9.3.3. Colombia Ankylosing Spondylitis Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug
      • 9.3.3.2.2. By End Use

10. Middle East and Africa Ankylosing Spondylitis Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug
  • 10.2.2. By End Use
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Ankylosing Spondylitis Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug
      • 10.3.1.2.2. By End Use
  • 10.3.2. Saudi Arabia Ankylosing Spondylitis Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug
      • 10.3.2.2.2. By End Use
  • 10.3.3. UAE Ankylosing Spondylitis Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug
      • 10.3.3.2.2. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition
• 12.2. Drug Development
• 12.3. Recent Developments

13. Global Ankylosing Spondylitis Therapeutics Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Business Overview
• 14.2. Application Offerings
• 14.3. Recent Developments
• 14.4. Key Personnel
• 14.5. SWOT Analysis
  • 14.5.1. AbbVie, Inc.
  • 14.5.2. Amgen, Inc.
  • 14.5.3. Pfizer, Inc.
  • 14.5.4. Novartis AG
  • 14.5.5. Eli Lilly and Company
  • 14.5.6. UCB, Inc.
  • 14.5.7. Johnson & Johnson Services, Inc.
  • 14.5.8. Merck & Co., Inc.

15. Strategic Recommendations

About Us & Disclaimer